Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Appointed director
Aptevo Therapeutics Inc. (APVO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
07/18/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
06/02/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
03/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/13/2023 8-K Quarterly results
01/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors New PD-L1 x CD40 Candidate Built on Proprietary ADAPTIRä Platform, Enters Pre-Clinical Pipeline"
12/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naïve"
11/10/2022 8-K Quarterly results
Docs: "Updated Results from a Phase 1study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 ADAPTIR™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome” will be presented on Sunday, December 11, 2022 from 6:00 PM-8:00 PM Central time"
11/04/2022 8-K Quarterly results
09/19/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a “May Proceed” Notification for the ALG.APV-527 IND Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types"
08/11/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/07/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/30/2022 8-K/A Other Events, Financial Statements and Exhibits  Interactive Data
03/29/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status"
03/24/2022 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE"
02/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Goodwin Procter LLP"
02/17/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Purchase Agreement, by and between the Company and Lincoln Park",
"Registration Rights Agreement, by and between the Company and Lincoln Park"
02/09/2022 8-K Quarterly results
01/21/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EXHIBIT_99_1"
11/23/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cancers 2021, 13, Aug 15;13:4113. Click here to view the publication: https://doi.org/10.3390/cancers."
11/12/2021 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS THIRD QUARTER FINANCIAL RESULTS WITH BUSINESS HIGHLIGHTS"
11/05/2021 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Financial Statements and Ex...
Docs: "Amendment No. 1 to Rights Agreement, between the Company and Broadridge Corporate Issuer Solutions, Inc., as Rights Agent"
08/27/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
Docs: "APTEVO THERAPEUTICS REPORTS SECOND QUARTER FINANCIAL RESULTS WITH BUSINESS HIGHLIGHTS"
06/28/2021 8-K Quarterly results
05/27/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy